Pfizer Inc. $PFE Shares Bought by Nexus Investment Management ULC

Nexus Investment Management ULC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 991,225 shares of the biopharmaceutical company’s stock after purchasing an additional 19,700 shares during the quarter. Pfizer makes up about 3.4% of Nexus Investment Management ULC’s portfolio, making the stock its 13th biggest holding. Nexus Investment Management ULC’s holdings in Pfizer were worth $24,682,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Horizon Financial Services LLC boosted its stake in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new stake in Pfizer during the 4th quarter worth $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the 3rd quarter worth $29,000. Darwin Wealth Management LLC acquired a new stake in Pfizer during the 2nd quarter worth $32,000. Finally, True Wealth Design LLC boosted its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer filed a new Phase 1 study (PF-07328948), signaling continued pipeline investment and R&D momentum that supports longer-term growth prospects. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Optimistic retail/analyst takes: at least one bullish piece argues PFE looks undervalued and could be a strong buy over a multi-year horizon, which can support investor appetite for the stock on dips. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Market correlation: some coverage notes today’s action is tied to broader S&P 500 moves rather than company-specific news, which can amplify price swings independent of fundamentals. Pfizer Inc. Market Action Tied To S&P 500 Index Movement
• Neutral Sentiment: Feature pieces weigh reasons to watch PFE while advising caution — helpful context for investors assessing valuation versus near-term risks. 2 Reasons to Watch PFE and 1 to Stay Cautious
• Neutral Sentiment: Sector competitive landscape: coverage of the expanding “diabesity” (GLP‑1) market highlights big opportunities for peers like Lilly and Novo Nordisk — an indirect signal that competition and missed participation in the category could pressure Pfizer’s long‑term growth narrative. The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, which prompted immediate selling pressure and raises short‑term uncertainty about their COVID franchise strategy. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports that a Washington proposal could impose steep tariffs (or a 100% framework) on drugmakers without pricing agreements added regulatory and political risk that can pressure valuations in the near term. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Market reaction note: headline summaries show the stock has moved lower amid these combined factors, which explains today’s downward price action versus recent highs. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Pfizer Trading Down 2.6%

Shares of PFE stock opened at $27.10 on Wednesday. The company’s 50-day moving average price is $27.14 and its 200-day moving average price is $25.89. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market cap of $154.07 billion, a price-to-earnings ratio of 19.92 and a beta of 0.43. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. Guggenheim boosted their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.19.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.